Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 4/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.38 |
| ▸ | TLR4 | O00206 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15034177 | 0.86 | — | — | |
| SCHEMBL16969326 | 0.82 | SIGMAR1 (0.36) | ALDH1A1MAPT | |
| SCHEMBL10049903 | 0.82 | SIGMAR1 (0.39) | ALDH1A1MAPTALOX15TDP1 | |
| SCHEMBL27367010 | 0.82 | CACNA2D1 (0.38) | TLR8TLR7TLR9 | |
| SCHEMBL15297033 | 0.81 | HTR2A (0.37) | ALDH1A1MAPTHTR2C | |
| SCHEMBL10049902 | 0.81 | SIGMAR1 (0.41) | MEN1ALDH1A1MAPTALOX15KMT2A | |
| SCHEMBL23418737 | 0.80 | TLR8 (0.41) | HTR2CTLR8PIM1 | |
| SCHEMBL15448695 | 0.79 | TP53 (0.33) | MEN1ALDH1A1MAPTPKMKMT2A | |
| SCHEMBL26157220 | 0.79 | TP53 (0.33) | MEN1ALDH1A1MAPTPKMKMT2A | |
| SCHEMBL12413742 | 0.79 | MEN1 (0.40) | CHRNB2CHRNA4GABRA1GABRB2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030012-B2 | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-07-24 | — | — | US | disclosed |
| US-10030012-B2 | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-07-24 | — | — | US | disclosed |
| US-9828373-B2 | 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-11-28 | — | — | US | disclosed |
| US-20170183338-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-06-29 | — | — | US | disclosed |
| US-20170183338-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-06-29 | — | — | US | disclosed |
| US-20170121323-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-05-04 | — | — | US | disclosed |
| US-9593106-B2 | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-03-14 | — | — | US | disclosed |
| US-9593106-B2 | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-03-14 | — | — | US | disclosed |
| US-9403798-B2 | Triazinone compound and T-type calcium channel inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150376179-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2015-12-31 | — | — | US | disclosed |
| US-20110136789-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136789-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136789-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2205589-B1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2205589-B1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010115491-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| EP-2205589-A2 | C-MET PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009153589-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009045992-A2 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009045992-A2 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136789-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | CHRNB2 4773/4885CHRNA4 4864/4885GABRA1 3628/4885 |
| US-10030012-B2 | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists | CHRM1, CHRM2, CHRM4 | CHRNB2 24/4885CHRNA4 9/4885GABRA1 308/4885 |
| US-20170121323-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF | CDK6, CDK4, CDK7 | CHRNB2 4809/4885CHRNA4 4572/4885GABRA1 4665/4885 |
| US-20150376179-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | CHRNB2 24/4885CHRNA4 9/4885GABRA1 308/4885 |
| US-20170183338-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | CHRNB2 24/4885CHRNA4 9/4885GABRA1 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.